Predilife SA has raised about €3.6 million in gross proceeds from its IPO on the Euronext Growth Paris market.
The Paris-based biotechnology company issued 386,154 shares through an open-price offering and a simultaneous global placement for €9.30 apiece. The share price was at the lower end of the price range that was previously set at €8.76 to €11.84.
Predilife's shares will start trading on the Euronext Growth Paris market on Dec. 21 under the symbol ALPRE.
The company plans to use the proceeds for the commercialization of MammoRisk, an imaging tool for assessing breast cancer risk. Predilife will also use the amount raised in the IPO for repayment of loans to Bpifrance.
Stéphane Ragusa is the chariman and CEO of Predilife, a company that uses statistical data to develop mathematical models for risk profiling of individuals regarding the occurrence of serious diseases.